These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 12634225

  • 21. An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes.
    Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsuhashi H, Ishibashi H, Eguchi K.
    Rheumatology (Oxford); 2005 Apr; 44(4):443-8. PubMed ID: 15695308
    [Abstract] [Full Text] [Related]

  • 22. The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
    Vrenken TE, Buist-Homan M, Kalsbeek AJ, Faber KN, Moshage H.
    J Hepatol; 2008 Nov; 49(5):799-809. PubMed ID: 18809221
    [Abstract] [Full Text] [Related]

  • 23. Estrogens interfere with leflunomide modulation of cytokine production by human activated monocytes.
    Montagna P, Soldano S, Brizzolara R, Villaggio B, Triolo P, Clerico P, Meroni M, Sulli A, Seriolo B, Molfetta L, Cutolo M.
    Ann N Y Acad Sci; 2010 Apr; 1193():30-5. PubMed ID: 20398005
    [Abstract] [Full Text] [Related]

  • 24. Interleukin-4 inhibits prostaglandin E2 production by freshly prepared adherent rheumatoid synovial cells via inhibition of biosynthesis and gene expression of cyclo-oxygenase II but not of cyclo-oxygenase I.
    Sugiyama E, Taki H, Kuroda A, Mino T, Yamashita N, Kobayashi M.
    Ann Rheum Dis; 1996 Jun; 55(6):375-82. PubMed ID: 8694577
    [Abstract] [Full Text] [Related]

  • 25. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
    Sawamukai N, Saito K, Yamaoka K, Nakayamada S, Ra C, Tanaka Y.
    J Immunol; 2007 Nov 15; 179(10):6479-84. PubMed ID: 17982036
    [Abstract] [Full Text] [Related]

  • 26. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.
    Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, Veale DJ, Breedveld FC, Emery P, Tak PP.
    Arthritis Rheum; 2000 Aug 15; 43(8):1820-30. PubMed ID: 10943872
    [Abstract] [Full Text] [Related]

  • 27. Selective inhibition of cyclooxygenase 2-generated prostaglandin E2 synthesis in rheumatoid arthritis synoviocytes by taurine chloramine.
    Kontny E, Rudnicka W, Kowalczewski J, Marcinkiewicz J, Maslinski W.
    Arthritis Rheum; 2003 Jun 15; 48(6):1551-5. PubMed ID: 12794822
    [Abstract] [Full Text] [Related]

  • 28. Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes.
    Bidgood MJ, Jamal OS, Cunningham AM, Brooks PM, Scott KF.
    J Immunol; 2000 Sep 01; 165(5):2790-7. PubMed ID: 10946311
    [Abstract] [Full Text] [Related]

  • 29. Increase of cyclooxygenase-2 expression by interleukin 15 in rheumatoid synoviocytes.
    Min SY, Hwang SY, Jung YO, Jeong J, Park SH, Cho CS, Kim HY, Kim WU.
    J Rheumatol; 2004 May 01; 31(5):875-83. PubMed ID: 15124245
    [Abstract] [Full Text] [Related]

  • 30. Mediators of inflammation are down-regulated while apoptosis is up-regulated in rheumatoid arthritis synovial tissue by polymerized collagen.
    Furuzawa-Carballeda J, Rodríquez-Calderón R, Díaz de León L, Alcocer-Varela J.
    Clin Exp Immunol; 2002 Oct 01; 130(1):140-9. PubMed ID: 12296865
    [Abstract] [Full Text] [Related]

  • 31. Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts.
    Lin N, Sato T, Ito A.
    Arthritis Rheum; 2001 Sep 01; 44(9):2193-200. PubMed ID: 11592385
    [Abstract] [Full Text] [Related]

  • 32. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
    Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomsic M, Suput D, Trdan T, Peterlin Masic L, Mrhar A, Dolzan V.
    Drug Metab Dispos; 2009 Oct 01; 37(10):2061-8. PubMed ID: 19581389
    [Abstract] [Full Text] [Related]

  • 33. Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures.
    Schmidt EM, Davies M, Mistry P, Green P, Giddins G, Feldmann M, Stoop AA, Brennan FM.
    Arthritis Rheum; 2013 Sep 01; 65(9):2262-73. PubMed ID: 23784528
    [Abstract] [Full Text] [Related]

  • 34. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade.
    Heinhuis B, Koenders MI, van Riel PL, van de Loo FA, Dinarello CA, Netea MG, van den Berg WB, Joosten LA.
    Ann Rheum Dis; 2011 Apr 01; 70(4):660-7. PubMed ID: 21187297
    [Abstract] [Full Text] [Related]

  • 35. Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes.
    Vergne P, Liagre B, Bertin P, Cook-Moreau J, Treves R, Beneytout JL, Rigaud M.
    J Rheumatol; 1998 Mar 01; 25(3):433-40. PubMed ID: 9517759
    [Abstract] [Full Text] [Related]

  • 36. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors.
    Yarilina A, Xu K, Chan C, Ivashkiv LB.
    Arthritis Rheum; 2012 Dec 01; 64(12):3856-66. PubMed ID: 22941906
    [Abstract] [Full Text] [Related]

  • 37. Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase.
    Blom AB, Radstake TR, Holthuysen AE, Slöetjes AW, Pesman GJ, Sweep FG, van de Loo FA, Joosten LA, Barrera P, van Lent PL, van den Berg WB.
    Arthritis Rheum; 2003 Apr 01; 48(4):1002-14. PubMed ID: 12687542
    [Abstract] [Full Text] [Related]

  • 38. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
    Woolley DE, Tetlow LC.
    Arthritis Res; 2000 Apr 01; 2(1):65-74. PubMed ID: 11219391
    [Abstract] [Full Text] [Related]

  • 39. [CTLA4-Ig interferes and downregulates the proinflammatory activities of rheumatoid synovial macrophages in monoculture].
    Brizzolara R, Soldano S, Montagna P, Sulli A, Seriolo B, Villaggio B, Triolo PF, Clerico P, Felli L, Molfetta L, Cutolo M.
    Reumatismo; 2011 Apr 01; 63(2):80-5. PubMed ID: 21776443
    [Abstract] [Full Text] [Related]

  • 40. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin.
    van Roon JA, van Vuuren AJ, Wijngaarden S, Jacobs KM, Bijlsma JW, Lafeber FP, Thepen T, van de Winkel JG.
    Arthritis Rheum; 2003 May 01; 48(5):1229-38. PubMed ID: 12746896
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.